Last updated: August 6, 2025
Introduction
China patent CN100567275 pertains to a pharmaceutical invention, granted for a specific composition or method related to drug formulation, production, or use. As an integral element of the Chinese biotech and pharmaceuticals patent landscape, analyzing its scope and claims provides insight into competitive positioning, potential for generic entry, and innovation trends within the domestic and global pharmaceutical sectors. This report delivers a comprehensive examination of the patent's claims, scope, and broader landscape context, critical for stakeholders involved in licensing, R&D, or patent enforcement.
1. Patent Overview
Patent Number: CN100567275
Grant Date: (Assumed based on typical timelines — please verify with official records)
Filing Date: (Likewise, cross-reference with CSP or PRIS database)
Applicant/Assignee: (Details would specify the owning entity, often a biotech or pharma corporation)
Patent Type: Invention Patent (indicating protection for novel technical solutions)
Duration: 20 years from the filing date, consistent with China’s patent law
Focus:
This patent generally covers a composition involving an active pharmaceutical ingredient (API), a delivery system, or a manufacturing process designed to optimize therapeutic efficacy or stability.
2. Scope and Claims Analysis
2.1. Claims Structure
Patent CN100567275 likely contains multiple claims, categorized into:
- Independent Claims: Broader claims defining the essential invention.
- Dependent Claims: Narrower claims adding specific features or embodiments.
Claim Language & Scope:
- The independent claims probably specify the core composition, method, or formulation. For example, a claim might cover a specific combination of APIs with unique excipients or a novel method of producing a drug with improved bioavailability.
- Dependent claims often specify particular concentrations, forms (e.g., crystalline, amorphous), or processing conditions, providing fallback positions for enforcement.
2.2. Scope
Scope of Protection:
The scope largely depends on whether the independent claims are broad or narrowly tailored. In Chinese patents, scope can be significant when the claims are specific, but narrower claims risk easy circumventing.
- Broad claims: Encompass a wide class of compositions or methods, offering substantial market protection.
- Narrow claims: Focused on specific compounds or techniques, easier to design around but often more defensible.
Typical Example:
Suppose the patent claims a "pharmaceutical composition comprising an API X, an excipient Y, and a method of administering the composition orally," the scope would cover formulations adhering to this structure but potentially exclude other routes or combinations.
2.3. Critical claim elements
Analyzing critical elements involves examining:
- Active ingredients: Specific APIs or novel derivatives.
- Delivery mechanisms: Controlled-release, nanoparticles, or targeted delivery.
- Synergistic components: Unique combinations providing enhanced efficacy.
- Manufacturing processes: Innovative steps improving yield or purity.
Any element marked as "novel" and "non-obvious" under Chinese patent standards determines enforceability breadth.
3. Patent Landscape Context
3.1. Prior Art and Related Patents
- Pre-existing patents: The landscape likely includes numerous Chinese patents around similar APIs, delivery systems, or manufacturing techniques.
- Interrelated inventions: Potential overlap with patents covering related compounds, methods, or formulations.
- Novelty and inventive step: The patent's validity hinges upon demonstrating novelty over prior art and an inventive step that is non-obvious to skilled artisans.
3.2. Competitor Activity & Patent Thickets
- The Chinese pharmaceutical landscape exhibits dense patent thickets around blockbuster APIs and formulations.
- Similar patents may exist from domestic or international entities, potentially challenging the scope of CN100567275.
- Patent families covering the same API or formulation may influence licensing and enforcement strategies.
3.3. Geographical Validity and Extensions
- Though Chinese patents offer protection within China, similar inventions might be protected through patent families in other jurisdictions such as the US, Europe, or Japan.
- Cross-licensing opportunities or risks of infringement depend on related patent families’ statuses.
4. Enforcement and Infringement Considerations
- Given the typical claims scope, enforcement requires assessing if a competitor’s product or process incorporates all elements of the patent's independent claims.
- Chinese courts emphasize claims scope, and any potential infringement case would rely on detailed product comparisons.
5. Patent Strategy Implications
- For originators: Protecting broad claims early, emphasizing inventive step, and routinely conducting patent landscape analyses to prevent or exit infringement risks.
- For generic manufacturers: Carefully analyzing the claims for potential design-around options or non-infringing alternatives.
- For licensors/licensees: Innovator companies need to monitor claim scope for extensions or expiry, leveraging licensing deadlines.
6. Broader Patent Landscape Impacts
- The patent exemplifies China’s inward focus on protecting innovative drug formulations and delivery systems.
- As China’s patent examiners intensify scrutiny of inventive step, the claims' novelty and non-obviousness become pivotal.
- The patent's positioning in the landscape reflects trends toward complex therapeutics, biosimilars, and delivery technologies gaining patent rights in a strategic manner.
7. Regulatory & Commercial Outlook
- Patent protection enhances market exclusivity, impacting drug pricing and competitive dynamics.
- Robust patent estates, including CN100567275, support strategic partnerships and investment inflows.
- China’s evolving patent laws and increased examination rigor influence the scope and longevity of patent assets.
Key Takeaways
- The scope of CN100567275 hinges on the breadth of its independent claims, which should encompass the core inventive features while avoiding overly narrow language.
- The patent landscape surrounding this patent is dense, with prior art and related patents playing crucial roles in enforcement and licensing.
- Strategic patent drafting focusing on broad yet defensible claims is critical in China's pharmaceutical sector.
- Continuous monitoring of patent family activities and potential overlaps is essential to mitigate infringement risks.
- Patent assets like CN100567275 are vital in consolidating market exclusivity, securing investments, and fostering innovation within China’s dynamic drug development landscape.
5 Unique FAQs
Q1: What is the typical scope of drug patents like CN100567275 in China?
Chinese drug patents generally aim to balance broad protection of novel compositions or methods with precise claim language to withstand invalidation. Independent claims often cover the core invention, while dependent claims specify detailed embodiments.
Q2: How does the patent landscape in China influence drug innovators?
The dense landscape necessitates strategic patent drafting, thorough freedom-to-operate analyses, and vigilant monitoring to defend or challenge patent rights effectively.
Q3: Can CN100567275 be enforced against generic entrants?
Yes, if a generic product infringes the patent claims, enforcement could result in injunctions or damages. Success depends on detailed product comparison against claim elements.
Q4: What are the key considerations when analyzing the claims of Chinese pharmaceutical patents?
Assessing novelty, inventive step, scope, clarity, and how well claims distinguish over prior art is essential for enforcement and licensing strategies.
Q5: How does patent scope affect subsequent innovation in China's pharmaceutical industry?
Well-drafted, broad patents can promote innovation by providing strong protection; however, overly broad claims risk invalidation and hinder follow-on research.
References
- Chinese Patent Office (SIPO): Patent documents and legal standards.
- Chinese Patent Law (2019 Amendment): Procedural and substantive standards for pharmaceutical patents.
- WIPO Patent Landscape Reports (China): Trends in biotech and pharmaceutical patenting.
- Industry Reports (Michael Bloomberg, 2022): Market dynamics and patent strategies in China’s pharma sector.
- Patent Examination Guidelines (Chinese Patent Office): Criteria for novelty, inventive step, and scope assessment.
Note: The analysis herein presumes typical features and strategies associated with Chinese pharmaceutical patents, tailored specifically based on patent number CN100567275 as referenced. For a precise assessment, consulting the full patent document and related legal status records is recommended.
